Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 9;286(49):42594-42602.
doi: 10.1074/jbc.M111.267922. Epub 2011 Sep 29.

Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity

Jennifer E Towne  1 , Blair R Renshaw  2 , Jason Douangpanya  2 , Brian P Lipsky  2 , Min Shen  3 , Christopher A Gabel  2 , John E Sims  2
Affiliations

Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity

Jennifer E Towne et al. J Biol Chem. .

Abstract

IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36Ra (formerly IL-1F5) has been reported to antagonize IL-36γ. However, our previous attempts to demonstrate IL-36Ra antagonism were unsuccessful. Here, we demonstrate that IL-36Ra antagonist activity is dependent upon removal of its N-terminal methionine. IL-36Ra starting at Val-2 is fully active and capable of inhibiting not only IL-36γ but also IL-36α and IL-36β. Val-2 of IL-36Ra lies 9 amino acids N-terminal to an A-X-Asp motif conserved in all IL-1 family members. In further experiments, we show that truncation of IL-36α, IL-36β, and IL-36γ to this same point increased their specific activity by ∼10(3)-10(4)-fold (from EC(50) 1 μg/ml to EC(50) 1 ng/ml). Inhibition of truncated IL-36β activity required ∼10(2)-10(3)-fold excess IL-36Ra, similar to the ratio required for IL-1Ra to inhibit IL-1β. Chimeric receptor experiments demonstrated that the extracellular (but not cytoplasmic) domain of IL-1Rrp2 or IL-1R1 is required for inhibition by their respective natural antagonists. IL-36Ra bound to IL-1Rrp2, and pretreatment of IL-1Rrp2-expressing cells with IL-36Ra prevented IL-36β-mediated co-immunoprecipitation of IL-1Rrp2 with IL-1RAcP. Taken together, these results suggest that the mechanism of IL-36Ra antagonism is analogous to that of IL-1Ra, such that IL-36Ra binds to IL-1Rrp2 and prevents IL-1RAcP recruitment and the formation of a functional signaling complex. In addition, truncation of IL-36α, IL-36β, and IL-36γ dramatically enhances their activity, suggesting that post-translational processing is required for full activity.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Antagonistic activity of IL-36Ra requires removal of its N-terminal methionine. A, Jurkat reporter cells were incubated with a dose titration of huIL-36Ra (starting at 1.18 μm, 1:5 dilutions) expressed in E. coli or COS cells before stimulation with huIL-36γ (used at EC90 ∼ 0.138 μm). B, cells were incubated with a dose titration of huIL-36Ra beginning with Met-1 (M1) or Val-2 (V2) (starting at 1.18 μm, 1:5 dilutions) before stimulation with huIL-36γ (used at EC90 ∼ 0.138 μm). C, cells were incubated with a dose titration of huIL-36Ra(V2) (starting at 2.94 μm, 1:5 dilutions) before stimulation with huIL-36α (used at EC90 ∼ 0.576 μm), huIL-36β (used at EC90 ∼ 0.209 μm), or huIL-36γ (used at EC90 ∼ 0.435 μm). In A–C, all cells were treated with the huIL-36Ra proteins for 15 min before the addition of agonist for 5 h, although in other experiments, we have shown that simultaneous addition of IL-36Ra with the IL-36 agonist is equally effective as preincubation with IL-36Ra prior to agonist addition. IL-8p-luciferase activity was measured and is expressed as a percentage of the luciferase activity in the absence of IL-36Ra (set at 100%). IL-36Ra(V2) IC50 values were similar and ranged from 0.001 to 0.006 μm. Data are means ± S.D. from one experiment (in duplicate or triplicate) that is representative of at least three similar experiments with comparable results.
FIGURE 2.
FIGURE 2.
Truncating IL-36α, IL-36β, and IL-36γ enhances their activity. A, alignment of the protein sequences of human IL-36Ra, IL-36α, IL-36β, and IL-36γ highlighting the A-X-Asp (@XD) motif, the position 9 amino acids N-terminal to it, and the huIL-36γ truncations (positions −8, −9, and −10) generated for activity testing. B, Jurkat reporter cells were stimulated with a dose titration of full-length (FL) huIL-36γ (starting at 2.94 μm, 1:5 dilutions) or huIL-36γ truncated at position −8, −9, or −10 (with respect to the A-X-Asp motif) (huIL-36γ(Q17) starting at 2.94 μm, huIL-36γ(S18) starting at 0.005 μm, and huIL-36γ(M19) starting at 2.94 μm; 1:5 dilutions). C, Jurkat reporter cells were stimulated with titrations of full-length (starting at 2.35 μm) or appropriately truncated (starting at 0.002 μm) huIL-36α, IL-36β, and IL-36γ (1:5 dilutions) for comparison. In B and C, all cells were stimulated with the IL-36 proteins for 5 h before measurement of luciferase activity. Data are expressed as relative light units (R.L.U) and are means ± S.D. from one experiment (in duplicate) that is representative of at least three similar experiments with comparable results.
FIGURE 3.
FIGURE 3.
Large molar excess of IL-36Ra is required to block truncated IL-36 agonist activity. A, Jurkat reporter cells were treated with a dose titration of huIL-36Ra(V2) (starting at 2.94 μm, 1:5 dilutions) for 15 min before the addition of human IL-36α(K6), IL-36β(R5), and IL-36γ(S18) at their EC90 concentrations (IL-36α(K6), ∼0.118 nm; IL-36β(R5), ∼0.019 nm; and IL-36γ(S18), ∼0.294 nm) for 5 h. IL-8p-luciferase activity was measured and is expressed as a percentage of the luciferase activity in the absence of IL-36Ra (set at 100%). IL-36Ra IC50 values were similar for inhibition of IL-36α, IL-36β, and IL-36γ and ranged from 0.003 to 0.006 μm. B, Jurkat cells were transiently transfected with huIL-1R1 and the IL-8p-luciferase reporter. Cells were treated with a dose titration of huIL-1Ra (starting at 0.294 μm, 1:5 dilutions) for 15 min before the addition of huIL-1β at the EC90 concentration (IL-1β, ∼0.647 pm). IL-8p-luciferase activity was measured and is expressed as a percentage of the luciferase activity in the absence of inhibitor. The ratios of IL-1Ra to IL-1β and of IL-36Ra to IL-36 agonist were calculated and are plotted versus the percentage of IL-8p-luciferase activity. The ratios of IL-36Ra(V2) to full-length (FL) and truncated IL-36 agonists were calculated from Fig. 1C and panel A. Data are means ± S.D. from one experiment (in duplicate) that is representative of at least three similar experiments with comparable results.
FIGURE 4.
FIGURE 4.
IL-36Ra blocks IL-36 ligand binding to the IL-1Rrp2 receptor and the subsequent recruitment of IL-1RAcP. A, Jurkat cells were transfected with the IL-8p-luciferase reporter along with various receptor constructs. Cells were treated with 1.18 μm huIL-1Ra or huIL-36Ra(V2) for 15 min before the addition of full-length (FL) huIL-36α (0.059 μm), truncated (Trunc.) huIL-36α (0.006 μm), or huIL-1β (0.059 nm) for 5 h. Luciferase activity was measured and is expressed as relative light units (R.L.U). Data are means ± S.D. from one experiment (in quadruplicate) that is representative of at least three similar experiments with comparable results. B, murine BaF3 cells stably overexpressing muIL-1Rrp2 were pretreated with 0.2, 0.5, 5, or 50 μg/ml muIL-36Ra(V2) or the BSA control for 1 min before the addition of 0.1 μg/ml muIL-36β(S4) for 4 min at 37 °C. Control samples receiving no muIL-36Ra(V2) or BSA were treated with 50 μg/ml full-length muIL-36β, 0.1 μg/ml muIL-36β(S4), or medium alone. muIL-1RAcP was immunoprecipitated from cell lysates overnight with an anti-muIL-1RAcP antibody. Co-immunoprecipitation of IL-1Rrp2 was detected with an anti-muIL-1Rrp2 antibody by Western blotting. Data are representative of at least three similar experiments with comparable results.
FIGURE 5.
FIGURE 5.
IL-36Ra(V2) and IL-36α(K6) can compete with anti-IL-1Rrp2 antibody binding. A, Jurkat reporter cells were preincubated with or without human IL-36α(K6), IL-36Ra(V2), or IL-1Ra for 15 min before staining with anti-huIL-1Rrp2 antibody or anti-FLAG control antibody. B, Jurkat reporter cells were preincubated with or without human IL-36α(K6), IL-36Ra(V2), or IL-1Ra for 15 min before staining with anti-huIL-1RAcP antibody or anti-FLAG control antibody. Data are representative of at least two similar experiments with comparable results. PE, phycoerythrin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dunn E., Sims J. E., Nicklin M. J., O'Neill L. A. (2001) Trends Immunol. 22, 533–536 - PubMed
    1. Sims J. E., Smith D. E. (2010) Nat. Rev. Immunol. 10, 89–102 - PubMed
    1. O'Neill L. A. (2008) Immunol. Rev. 226, 10–18 - PubMed
    1. Greenfeder S. A., Nunes P., Kwee L., Labow M., Chizzonite R. A., Ju G. (1995) J. Biol. Chem. 270, 13757–13765 - PubMed
    1. Born T. L., Thomassen E., Bird T. A., Sims J. E. (1998) J. Biol. Chem. 273, 29445–29450 - PubMed